0

524727

SDL

img img img img
No Data Available

Span Divergent Limited Share Price Update

As of the latest trading session, Span Divergent Limited is trading at ₹36.67, up by ₹0.00 or 0.00% from its previous close. The stock has moved between ₹36.67 and ₹36.67 today. Over the past year, the stock has delivered a return of 51.84%. In the last month, it has returned 0.00%.

Investment Returns

Over 1 Month 0.00% Over 3 Months 4.98% Over 6 Months 19.95% Over 1 Year 51.84%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Span Divergent Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 26.60
  • P/E Ratio (TTM) 33.04
  • Beta -0.07
  • Book Value / share 56.56
  • Return on equity 1.25%
  • EPS (TTM) 0.67
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.14
info icon alternate text

Span Divergent Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.53
Net Profit 0.14
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.25
EBITDA 0.22
Effective Tax Rate (%) 6.66
Particulars SEP 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.45
Net Profit 0.12
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.22
EBITDA 0.18
Effective Tax Rate (%) -8.33
Particulars JUN 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.41
Net Profit 0.42
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.76
EBITDA 0.49
Effective Tax Rate (%) 2.32
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.54
Net Profit 0.13
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.24
EBITDA 0.20
Effective Tax Rate (%) 7.14
Particulars DEC 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.42
Net Profit 0.23
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.43
EBITDA 0.32
Effective Tax Rate (%) 7.69
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 1.84
Net Profit 0.84
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 1.54
EBITDA 1.23
Effective Tax Rate (%) 14.28
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 2.04
Net Profit 1.51
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 2.76
EBITDA 1.85
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 1.88
Net Profit -3.34
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -6.11
EBITDA -2.88
Effective Tax Rate (%) -1.21
Particulars MAR 2022 (Values in Cr)
Revenue 0.00
Operating Expense 2.02
Net Profit -7.76
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -14.20
EBITDA -7.56
Effective Tax Rate (%) 3.96
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 2.08
Net Profit 0.00
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.00
EBITDA 0.71
Effective Tax Rate (%) 100.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share -5.14
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 1.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share -3.46
ROE % 2.06
ROCE % 5.89
Total Debt to Total Equity 0.00
EBITDA Margin 19.61
Particulars MAR 2023 (Values in Cr)
Book Value / Share -5.20
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 12.40
Particulars MAR 2022 (Values in Cr)
Book Value / Share 4.07
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.19
EBITDA Margin 11.59
Particulars MAR 2021 (Values in Cr)
Book Value / Share 22.01
ROE % -41.62
ROCE % -13.30
Total Debt to Total Equity 1.26
EBITDA Margin -19.19
Particulars MAR 2025 (Values in Cr)
Book Value / Share 63.63
ROE % 1.25
ROCE % 1.35
Total Debt to Total Equity 0.06
EBITDA Margin 46.58
Particulars MAR 2024 (Values in Cr)
Book Value / Share 62.47
ROE % 1.32
ROCE % 1.22
Total Debt to Total Equity 0.07
EBITDA Margin 41.36
Particulars MAR 2023 (Values in Cr)
Book Value / Share 59.73
ROE % 1.84
ROCE % 1.69
Total Debt to Total Equity 0.08
EBITDA Margin 54.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 65.86
ROE % 2.21
ROCE % 1.30
Total Debt to Total Equity 0.08
EBITDA Margin 54.59
Particulars MAR 2021 (Values in Cr)
Book Value / Share 80.06
ROE % -0.05
ROCE % 0.02
Total Debt to Total Equity 0.07
EBITDA Margin 45.21
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.03
Total Assets 23.20
Total Liabilities 23.20
Total Equity -8.84
Share Outstanding 0
Price to Book Ratio 0.45
Return on Assets (%) -3.95
Return on Capital (%) 115.34
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.92
Total Assets 24.18
Total Liabilities 24.18
Total Equity -7.56
Share Outstanding 0
Price to Book Ratio 0.27
Return on Assets (%) 4.03
Return on Capital (%) 95.25
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.39
Total Assets 25.59
Total Liabilities 25.59
Total Equity -8.35
Share Outstanding 0
Price to Book Ratio 0.22
Return on Assets (%) -19.75
Return on Capital (%) -319.99
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.19
Total Assets 27.82
Total Liabilities 27.82
Total Equity -2.93
Share Outstanding 0
Price to Book Ratio 0.19
Return on Assets (%) -35.21
Return on Capital (%) -117.52
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.84
Total Assets 34.43
Total Liabilities 34.43
Total Equity 7.21
Share Outstanding 0
Price to Book Ratio 0.16
Return on Assets (%) -16.22
Return on Capital (%) -24.41
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.42
Total Assets 39.95
Total Liabilities 39.95
Total Equity 34.75
Share Outstanding 0
Price to Book Ratio 0.45
Return on Assets (%) 2.10
Return on Capital (%) 2.29
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.37
Total Assets 38.46
Total Liabilities 38.46
Total Equity 34.12
Share Outstanding 0
Price to Book Ratio 0.27
Return on Assets (%) 3.92
Return on Capital (%) 4.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.24
Total Assets 37.64
Total Liabilities 37.64
Total Equity 32.62
Share Outstanding 0
Price to Book Ratio 0.22
Return on Assets (%) -8.86
Return on Capital (%) -9.49
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 40.86
Total Liabilities 40.86
Total Equity 35.97
Share Outstanding 0
Price to Book Ratio 0.19
Return on Assets (%) -18.98
Return on Capital (%) -20.13
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 49.92
Total Liabilities 49.92
Total Equity 43.72
Share Outstanding 0
Price to Book Ratio 0.16
Return on Assets (%) 0.00
Return on Capital (%) 0
Particulars MAR 2025 (Values in Cr)
Net Income -1.08
Cash from Operations 1.20
Cash from Investing -1.04
Cash from Financing -1.14
Net change in Cash -0.33
Free Cash Flow 1.20
Particulars MAR 2024 (Values in Cr)
Net Income 0.79
Cash from Operations 2.53
Cash from Investing 0.11
Cash from Financing -2.09
Net change in Cash 0.52
Free Cash Flow 2.92
Particulars MAR 2023 (Values in Cr)
Net Income -5.52
Cash from Operations 2.02
Cash from Investing 0.53
Cash from Financing -2.30
Net change in Cash 0.20
Free Cash Flow 2.19
Particulars MAR 2022 (Values in Cr)
Net Income -10.36
Cash from Operations 7.21
Cash from Investing -2.05
Cash from Financing -5.49
Net change in Cash -0.51
Free Cash Flow 7.21
Particulars MAR 2021 (Values in Cr)
Net Income -6.10
Cash from Operations -0.06
Cash from Investing 1.98
Cash from Financing -1.40
Net change in Cash 0.36
Free Cash Flow -0.06
Particulars MAR 2025 (Values in Cr)
Net Income 0.98
Cash from Operations 0.66
Cash from Investing -1.10
Cash from Financing 0.14
Net change in Cash 0.04
Free Cash Flow 0.96
Particulars MAR 2024 (Values in Cr)
Net Income 1.51
Cash from Operations 0.58
Cash from Investing 0.15
Cash from Financing -0.56
Net change in Cash 0.12
Free Cash Flow 0.58
Particulars MAR 2023 (Values in Cr)
Net Income -3.29
Cash from Operations 0.69
Cash from Investing -0.35
Cash from Financing -0.02
Net change in Cash 0.20
Free Cash Flow 0.70
Particulars MAR 2022 (Values in Cr)
Net Income -8.07
Cash from Operations -0.23
Cash from Investing 0.42
Cash from Financing -0.20
Net change in Cash -0.08
Free Cash Flow -0.23
Particulars MAR 2021 (Values in Cr)
Net Income 0.02
Cash from Operations 0.43
Cash from Investing -0.57
Cash from Financing 0.29
Net change in Cash 0.09
Free Cash Flow 0.43
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
KESORAM INDUSTRIES LTD. 12.31 0.00 1.10 382.48 4.58 14.31
Max Financial Services Limited 1618.10 0.00 10.57 55843.02 1358.00 1891.35
MODI RUBBER LTD 132.95 21.20 0.60 332.91 100.25 167.80
THOMAS COOK (INDIA) LTD. 93.40 19.70 2.25 4393.35 86.15 188.45
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
FGP LTD. 12.01 200.17 4.18 14.29 7.32 13.70
KESORAM INDUSTRIES LTD. 12.31 38.47 1.17 382.48 4.58 14.31
MPIL CORPORATION LTD. 495.00 0.00 2.21 28.22 324.70 675.00
Max Financial Services Limited 1618.10 0.00 8.27 55843.02 1358.00 1891.35

Span Divergent Limited shareholding pattern

Holding
51.87%
48.12%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Span Divergent Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
36.67 0.00 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 36.40
  • 26 Days 33.60
  • 10 Days 35.80
  • 50 Days 30.90
  • 12 Days 35.60
  • 100 Days 28.50
  • 20 Days 34.40
  • 200 Days 27.10
36.67 PIVOT
First Support 36.67 First Resistance 36.67 Second Support 36.67 Second Resistance 36.67 Third Support 36.67 Third Resistance 36.67
RSI 73.48 ADX 46.33 MACD 1.96 Williams % R 0.00 Commodity Channel Index (CCI) 105.29
Date 2026-05-18 Week 1773.00 Same Day 1773.00 Month 677.00
1 Year -0.07 3 Year 0.39
Over 1 Month
0.00% down
Over 1 Year
51.84% down
Over 3 Months
4.98% down
Over 3 Years
30.49% down
Over 6 Months
19.95% down
Over 5 Years
22.12% down

Span Divergent Limited Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
16 Jul 2013 0.5 Final 18 Jul 2013 Equity shares
26 Jul 2011 1.0 Final 28 Jul 2011 Equity shares
18 Jun 2010 2.5 Final 22 Jun 2010 Equity shares
08 Aug 2008 2.0 Final 12 Aug 2008 Equity shares
10 Aug 2007 1.8 Final 14 Aug 2007 Equity shares
05 Sep 2005 0.0 Final 07 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
28 Jul 2010 27 Jul 2010 1:1

Top Gainers

Top Losers

Span Divergent Limited Share Price

Span Divergent Limited was initially incorporated as Span Diagnostics Private Limited on March 31, 1980 as a private limited Company. The Company was converted into a Public Limited Company and the name was changed to Span Diagnostics Limited on August 14, 1993. Thereafter, it attained the name to Span Divergent Limited in 2015. Initially, the Company manufactured a wide range of microbiological, immunological and bio-chemical diagnostic reagents, plastic accessories and allied products at the Udhna Plant.

The Company completed expansion-cum-modernisation and mechanisation of packing activities at Udhna. Acquiring three plots of land at GIDC Sachin admeasuring 33,897 sq. mtrs. which is situated near the State Highway and National Highway No.8.This project was finance by way of internal accruals of Rs.31.62 lakhs and balance from Term Loans of Rs.30 lakhs.

The Company entered into the technical arrangement with Bioprobe Netherland, Path U.S.A. Dynajen U.S.A. for manufacturing HIV Dipsticks, Myco-dot, Monoclonal anitbodies.

Company launched several new products developed by its R & D Center such as One Step Lateral Chromotography Based Assay for monitoring of pregnancy and Hepatitis to be marketed under the brand name of CRYSTAL as well as HIV Flow Through. The continuation distributorship arrangements with Murex Biotech UK Ltd which is now subsidiary of Abbott Diagnostics USA will also generate substantial business from the nitche market of the Blood Bank Segment.

During the year 2007-08, the Company renovated its production and administrative facilities. It acquired technology from France for production of Monoclonal Antibodies. A joint venture company in the name of Span Diagnostics SARL was formed in Nov'05, in the city of Compiegne, France. A joint venture company between Nihon Kohden Corporation, Japan and Span Diagnostics Ltd., India, started its operation from December 2008 and started manufacturing high quality reagents for Hematology Analysers for distribution and sale in India under license agreement with Nihon Kohden Corporation, Japan. The Company formed joint venture Company during year 2011-12 with Reindus Health (Pty) Limited.

During the year 2013 -14, Span Biotherapeutics Pvt. Ltd., subsidiary Company ceased to be a subsidiary Company with effect from May 27, 2013.

In 2014-15, the Company transferred its 95.24% stake held in subsidiary Span Biotronics Private Limited to M/s. Arkray Helathcare Private Limited and ceased to be a subsidiary Company with effect from March 05, 2015. The Company acquired 540 Equity Shares of Rand 1 Each from its existing shareholders of the Company. Upon acquisition of 540 Equity Shares of, Span Diagnostics South Africa (Pty) Limited, it became wholly owned overseas subsidiary Company.

During FY 2015-16, Company sold its investment in Span Nihon Kohden Diagnostics Private Limited which resulted into exceptional income. Subsequent to sale of investment held in Span Nihon Kohden Diagnostics Private Limited, Company's joint venture with the said Company came to an end. Similarly, the Company had sold its In-Vitro Diagnostics (IVD) Business to Japanese affiliated Company, M/S. Arkray Healthcare Private Limited through Slump Sale effective from March 05, 2015 and invested in different businesses through various subsidiaries.

During year 2015-16, Company incorporated new LLPs as under to carry out new businesses in FAB and HCLS verticals in respective entities comprising of Dryfruit Factory LLP; Span Diagnostics Products LLP; Biospan Scientific LLP and Aranya Agri Biotech LLP. M/s. BioSpan Contamination Control Solutions Private Limited became joint venture subsidiary Company effective on September 18, 2017.

In 2019-20, Company ventured into the diversified business in Food processing, Life science and Agri biotech. From 2022 onwards, it formed a separate division 'Spanyan Business Assistance' to focus on providing CXO services.

The Company has sold its In-Vitro Diagnostics Business Undertaking on March 05, 2015 and has invested in different businesses through various subsidiaries.

Parent organization Indian Private
NSE symbol [-]
Founded 1980
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Span Divergent Ltd?

Answer Field

Span Divergent Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 36.67 as on May 18 2026 11:19 AM.

What is the Market Cap of Span Divergent Ltd Share?

Answer Field

The market cap of Span Divergent Ltd for NSE ₹ 0.00 & for BSE ₹ 26.60 as on May 18 2026 11:19 AM.

What is the 52 Week High and Low of Span Divergent Ltd?

Answer Field

The 52 Week High and Low of Span Divergent Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 36.67 and ₹ 19.01.

What is 1 year return for Span Divergent Ltd?

Answer Field

The 1 year returns on the stock has been 51.84%.

What is the P/E Ratio of Span Divergent Ltd Share?

Answer Field

As on May 18 2026 11:19 AM the price-to-earnings (PE) ratio for Span Divergent Ltd share is 33.04.

What is the PB ratio of Span Divergent Ltd Share?

Answer Field

As on May 18 2026 11:19 AM, the price-to-book (PB) ratio for Span Divergent Ltd share is 56.56.

How to Buy Span Divergent Ltd Share?

Answer Field

You can trade in Span Divergent Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Span Divergent Ltd Share on Bajaj Broking App?

Answer Field

To buy Span Divergent Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Span Divergent Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|